Important MeSH terms and keywords used were: glucagon-like peptide 1 (GLP-1), GLP-1 analogue, incretin, dipeptidyl peptidase 4 (DPP-4) inhibitor, atherosclerosis, arteriosclerosis, atherogenesis, plaque, intima media thickness (IMT), flow-mediated dilation (FMD), adiponectin, leptin, endothelin, E-selectin, resistin, pentraxin, brain natriuretic peptide (BNP), monocyte chemotactic protein (MCP), vascular cell adhesion molecule-1 (VCAM-1), plasminogen activator inhibitor-1 (PAI-1), tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), high sensitivity C-reactive protein (hs-CRP), triglyceride and cholesterol
If GLP-1 therapy changes the timing and location of that absorption, the hormone levels in your bloodstream may not reach therapeutic concentrations reliably
Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease
[DOI] [Google Scholar] Reddy NM, Kleeberger SR, Bream JH, Fallon PG, Kensler TW, Yamamoto M, Reddy SP
These changes can significantly impact an individual's facial appearance and self-image
Stephenson LA, Wenger CB, ODonovan BH, Nadel ER (1984) Circadian rhythm in sweating and cutaneous blood flow
